Johnson & Johnson (JNJ) Tops Q2 EPS by 22c, Updates FY Guidance
Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.48, $0.22 better than the analyst estimate of $2.26. Revenue for the quarter came in at $23.31 billion versus the consensus estimate of $22.19 billion.
GUIDANCE:
Johnson & Johnson sees FY2021 EPS of $9.60-$9.70, versus the consensus of $9.52. Johnson & Johnson sees FY2021 revenue of $93.8-94.6 billion, versus the consensus of $91.3 billion.
($ in Billions, except EPS) | April 2021 | July 2021 (Base Business) | July 2021 (incl. COVID Vx) |
Adjusted Operational Sales1,2 Change vs. Prior Year | 8.7% - 9.9% | 9.5% - 10.5% | 12.5% - 13.5% |
Operational Sales2 Change vs. Prior Year | $89.3B - $90.3B 8.2% – 9.4% | $90.0B - $90.8B 9.0% – 10.0% | $92.5B - $93.3B 12.0% – 13.0% |
Estimated Reported Sales3 Change vs. Prior Year | $90.6B - $91.6B 9.7% – 10.9% | $91.3B - $92.1B 10.5% – 11.5% | $93.8B - $94.6B 13.5% – 14.5% |
Adjusted Operational EPS (Diluted)2,4 Change vs. Prior Year | $9.30 - $9.45 15.8% - 17.7% | $9.50 - $9.60 18.4% - 19.6% | |
Adjusted EPS (Diluted)3,4 Change vs. Prior Year | $9.42 - $9.57 17.3% - 19.2% | $9.60 - $9.70 19.6% - 20.8% |
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.